By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Monday that its board has approved a new $200 million stock repurchase program.
The board had previously approved a $100 million stock buyback program in March.
Registering provides access to this and other free content.
Already have an account?Login Now.
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.
A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.
In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.